Spinraza tops Q1 revenue in SMA mkt with KRW 17.7 billion
By Nho, Byung Chul | translator Kang, Shin-Kook
24.06.28 05:53:20
가나다라
0
Zolgensma sells KRW 1.8 billion, Evrysdi KRW 1.2 billion
Ultra-high-priced orphan drugs..insurance prices of Spinraza, Evrysdi, and Zolgensma are KRW 92.35 million, KRW 1.98172 billion, and KRW 9.52 million, respectively
Spinraza-Zolgensma are directly injected... Evrysdi is administered orally
▲(From the left) Spinraxa Inj, Zolgensma Inj, and Evrysdi for spinal muscular atrophy
Biogen Korea's Spinraza remains the No. 1 drug for spinal muscular atrophy (SMA) in the KRW 80 billion market.However, its performance has been somewhat sluggish due to the launch of competitors such as Roche Korea’s Evrysdi and Novartis’s Zolgensma.
In terms of drug distribution performance, Spinraza's sales in Q1 of this year were KRW 17.7 billion, 9 to 14 times higher than that of Zolgensma (KRW 1.8 billion) and Evrysdi (KRW 1.2 billion).
Sales of Spinraza (nusinersen sodium) were in the range of KRW 72.2 billion, KRW 61.2 billion, KRW 62.3 billion, and KRW 58.9 billion, in 2020, 2021, 2022, and 2023, respectively.
Zolgensma (onasemnogene abeparvovec),
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)